Clearmind Expands IP Portfolio with Hong Kong Patent Filing for PTSD Therapeutics — Clearmind Medicine Inc.

Event summary

Clearmind Medicine filed a patent application in Hong Kong for novel psychedelic compounds targeting PTSD and other mental health disorders.
The filing is part of an exclusive global licensing agreement with Yissum Research Development Company.
The global PTSD treatment market is projected to grow from USD 18.5 billion in 2025 to USD 30.2 billion by 2035, at a CAGR of 5.0%.
Clearmind's IP portfolio now includes nineteen patent families with 32 granted patents.

The big picture

Clearmind's patent filing in Hong Kong strengthens its global IP strategy, targeting a rapidly growing PTSD treatment market. The move underscores the company's focus on expanding into high-potential regions while leveraging its exclusive licensing agreements to drive innovation in neuroplastogen-derived therapeutics.

What we're watching

Market Expansion: How Clearmind's strategic entry into the Asian market through Hong Kong will impact its long-term value creation.
Regulatory Dynamics: Whether Clearmind can successfully navigate regulatory requirements to advance its development program globally.
Competitive Positioning: The pace at which Clearmind can sustain its IP portfolio growth and maintain a competitive edge in the PTSD therapeutics market.